Global /Sweden /Healthcare /Drug Manufacturers - General /ONCOZ

OncoZenge AB (publ)

ONCOZ

• STO: ONCOZ • Delayed

6.38SEK 3.4%

0.6735 USD

As of 7 June 2026, OncoZenge AB (publ) has a market cap of $9.25M USD, ranking #41703 globally and #657 in Sweden. It ranks #3696 in the Healthcare sector, and #1202 in the Drug Manufacturers - General industry.

Global Rank

41703

Country Rank

657

Sector Rank

3696

Industry Rank

1202

Key Stats

Market Cap

$9.25MUSD

86.68M SEK

Enterprise Value

$9.55MUSD

90.46M SEK

Revenue (TTM)

$297.02KUSD

2.78M SEK

Net Income (TTM)

-$1.7MUSD

-15.94M SEK

PS Ratio

31.1

PB Ratio

10.2

Company Profile

Country (HQ)

Sweden

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Stian Kildal open_in_new

Employees

Founded

2020

Website

oncozenge.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
3.4%	3%	10%	22%	8.8%	-8.7%	33%	-27%	-43%

News

Markets

Exchange	Ticker	Price	Quotes
Nasdaq Stockholm (STO) MIC: XSTO PRIMARY	ONCOZ OncoZenge AB Ordinary Shares ISIN: SE0015504097 Shares Out.: Shares Outstanding: 14.048M¹ Shares Float: 7.726M² TV: TradingView: OMXSTO: ONCOZ SA: Stock Analysis: STO: ONCOZ YF: Yahoo Finance: ONCOZ.ST GF: Google Finance: STO: ONCOZ BA: Barron's: ONCOZ MS: Morningstar: XSTO: ONCOZ	6.38 SEK	TV: TradingView: OMXSTO: ONCOZ SA: Stock Analysis: STO: ONCOZ YF: Yahoo Finance: ONCOZ.ST GF: Google Finance: STO: ONCOZ BA: Barron's: ONCOZ MS: Morningstar: XSTO: ONCOZ

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About OncoZenge AB (publ)

OncoZenge AB (publ), a pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. It offers BupiZenge, which is in Phase 3 clinical trials for the treatment of pain in the oral cavity. The company was incorporated in 2020 and is headquartered in Bromma, Sweden.

Similar Companies

Industry: Drug Manufacturers - General (Sweden)

Name	Market Cap (USD) diff.	PE	Country
Swedish Orphan Biovitrum AB (publ) STO: SOBI	$14.88B 139.44B SEK 161K%	152.8	Sweden
Camurus AB (publ) STO: CAMX	$3.35B 31.37B SEK 36K%	42.8	Sweden
BioArctic AB (publ) STO: BIOA-B	$2.93B 27.5B SEK 32K%	26.9	Sweden
Swedencare AB (publ) STO: SECARE	$451.91M 4.24B SEK 5K%	85.9	Sweden
Vicore Pharma Holding AB (publ) STO: VICO	$300.96M 2.82B SEK 3K%	-	Sweden
Hansa Biopharma AB (publ) STO: HNSA	$294.01M 2.76B SEK 3K%	-	Sweden

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 8M%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 6M%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 4M%	97.4	United States
Roche Holding AG SIX: RO	$324.68B 256.25B CHF 4M%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$289.43B 215.59B GBP 3M%	27.6	United Kingdom
Novartis AG SIX: NOVN	$277.35B 218.9B CHF 3M%	20.5	Switzerland

chevron_leftBack